Cue Biopharma, Inc.

https://www.cuebiopharma.com

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company headquartered in Boston, Massachusetts, at 40 Guest Street. The company's core business revolves around developing a novel class of therapeutic biologics designed to selectively engage and modulate disease-relevant T cells. Its mission is to revolutionize immunotherapy, creating more effective treatments for challenging diseases and transforming patient care in oncology and autoimmune disorders by harnessing the power of the immune system to establish a new standard of care.

At the heart of Cue Biopharma's approach is its proprietary Immuno-STAT™ (Selective Targeting and Alteration of T Cells) platform, which engineers biologics to mimic natural immune signals to selectively expand and activate specific immune cells, aiming to restore immune function and balance. The company's pipeline includes the CUE-100 series for oncology, the CUE-400 series for autoimmune diseases, and the CUE-500 series for targeted cell depletion, also addressing autoimmune and inflammatory conditions. Key product candidates include CUE-101 in oncology, CUE-401 for autoimmune diseases advancing towards Phase 1, and CUE-501. Additionally, Cue Biopharma recently expanded its pipeline by licensing Ascendant-221, a Phase 2 clinical-stage anti-IgE antibody for allergic diseases.

In recent notable developments, Cue Biopharma announced the appointment of Shao-Lee Lin, M.D., Ph.D., as its new Chief Executive Officer, President, and Director on April 30, 2026. This leadership change coincided with a significant expansion of its pipeline through an exclusive license agreement with Ascendant Health Sciences Ltd. for Ascendant-221, involving a $15 million upfront payment and potential milestones up to $676.5 million. The company also secured a $30 million private placement financing to advance its clinical pipeline and for general corporate purposes. Cue Biopharma is currently implementing a 1-for-30 reverse stock split. The company is positioned as a clinical-stage biopharmaceutical firm focused on delivering targeted immunotherapies across high-growth sectors of oncology and autoimmune/inflammatory diseases, aiming to avoid the adverse effects associated with broad systemic immune modulation.

Latest updates

Cue Biopharma Secures $30 Million PIPE Financing with Unusual Warrant Structure

Event summary

  • Cue Biopharma has raised $30 million via a private investment placement (PIPE) from accredited investors.
  • The financing involves pre-funded warrants for 2,727,272 shares and warrants for 1,363,636 shares, at an effective price of $11.00 per warrant.
  • The warrants have unusual terms: pre-funded warrants require shareholder approval before exercise and do not expire, while standard warrants expire in five years.
  • Proceeds will be used to advance the clinical pipeline, including Ascendant-221, working capital, and general corporate purposes.
  • The deal is expected to close on or about May 4, 2026, subject to customary closing conditions.

The big picture

Cue Biopharma's PIPE financing provides a near-term liquidity boost, but the unusual warrant structure raises questions about the company's capital-raising strategy and potential for future dilution. This move suggests the company may be facing challenges in accessing traditional public equity markets, potentially reflecting investor concerns about its clinical pipeline or overall valuation. The deal’s terms indicate a willingness by investors to provide capital, but on conditions that could create long-term shareholder risk.

What we're watching

Shareholder Approval
The requirement for shareholder approval before the pre-funded warrants can be exercised introduces a governance hurdle and potential for investor scrutiny, which could impact the company's future financing flexibility.
Dilution Risk
The warrant structure, particularly the non-expiring pre-funded warrants, presents a significant potential for future dilution if exercised, which could negatively impact existing shareholders.
Ascendant-221 Progress
The stated use of proceeds to advance Ascendant-221 will be critical to monitor; any setbacks or delays in its development could undermine investor confidence and the value of the PIPE financing.

Cue Biopharma Acquires Dual-Mechanism Anti-IgE Asset in $700M Deal

Event summary

  • Cue Biopharma licensed Ascendant Health’s Ascendant-221, a Phase 2 clinical-stage anti-IgE antibody, for global rights excluding China.
  • The deal includes a $15 million upfront payment and up to $676.5 million in milestone payments, totaling a potential $700 million.
  • Ascendant-221 is currently in a Phase 2 trial in China for chronic spontaneous urticaria (CSU), with results expected in 2H 2026.
  • Cue Biopharma plans to initiate a global Phase 2b trial in food allergy following the CSU data review.

The big picture

Cue Biopharma’s acquisition of Ascendant-221 represents a strategic pivot towards becoming a clinical-stage company with a more diverse pipeline. The $700 million potential deal underscores the continued investor interest in allergy therapies, a market valued at billions annually. This move also signals a shift away from Cue’s Immuno-STAT platform, potentially indicating a reassessment of its long-term viability.

What we're watching

Clinical Data
The results of the ongoing Phase 2 trial in China for CSU will be critical in determining the viability of Ascendant-221 and influencing Cue Biopharma’s Phase 2b food allergy trial design.
Financial Impact
Cue Biopharma’s ability to achieve the milestone payments tied to Ascendant-221’s development and commercialization will significantly impact its financial performance and burn rate.
Competitive Landscape
How Ascendant-221’s dual mechanism of action performs relative to existing IgE therapies, particularly Dupilumab, will dictate its market share and potential for best-in-class status.

Cue Biopharma Appoints ACELYRIN Founder as CEO Amid Pipeline Expansion

Event summary

  • Shao-Lee Lin, M.D., Ph.D., has been appointed CEO, President, and Board Director of Cue Biopharma, succeeding Interim CEO Lucinda Warren.
  • Dr. Lin previously served as Founder and CEO of ACELYRIN, securing over $1 billion in capital and taking the company public.
  • Cue Biopharma is accelerating development of CUE-401, a novel therapeutic targeting autoimmune diseases, with Phase 1 trials anticipated.
  • The company has added an ongoing Phase 2 program for allergic disease, details of which will be released in 2H2026.
  • Dr. Lin brings experience from AbbVie, Gilead Sciences, and Amgen, contributing to the development of multiple approved medicines.

The big picture

The appointment of a seasoned CEO with a track record of capital raising and public offerings signals a strategic shift for Cue Biopharma, moving it towards a more aggressive growth trajectory. This move comes as the biopharmaceutical sector increasingly focuses on targeted therapies for autoimmune and inflammatory diseases, a market with significant unmet need and potential for high returns. The addition of a Phase 2 program further underscores this ambition, though the company’s financial health remains a key vulnerability.

What we're watching

Execution Risk
Dr. Lin's success at ACELYRIN will be scrutinized as she navigates Cue Biopharma's more complex clinical and financial situation, particularly given the company's recent 'going concern' determination.
Pipeline Progression
The forthcoming details of the Phase 2 program for allergic disease will be critical in assessing Cue Biopharma’s near-term inflection point and overall pipeline value.
Governance Dynamics
The board's rationale for selecting Dr. Lin, and her subsequent decisions regarding resource allocation and strategic direction, will reveal the extent of their commitment to transforming Cue Biopharma into a clinical-stage company.

Cue Biopharma Executes 1-for-30 Reverse Split to Maintain Nasdaq Listing

Event summary

  • Cue Biopharma (CUE) approved and will implement a 1-for-30 reverse stock split, effective April 23, 2026.
  • The split aims to increase the per-share market price to regain compliance with Nasdaq’s minimum bid price requirement.
  • The reverse split will reduce the number of outstanding shares from approximately 97.7 million to roughly 3.3 million.
  • Shareholders approved the split at the company’s Annual Meeting on April 13, 2026.
  • Existing stock options, warrants, and equity incentive plans will be adjusted proportionally.

The big picture

The reverse stock split is a common, albeit often temporary, measure taken by companies facing delisting threats. It signals underlying financial distress and a lack of investor confidence, despite Cue Biopharma’s innovative Immuno-STAT platform and lead asset CUE-401. While the split provides a short-term reprieve, the company’s long-term viability depends on demonstrating clinical and commercial success.

What we're watching

Listing Stability
The success of the reverse split hinges on whether it sustainably elevates the share price above Nasdaq’s minimum requirement, avoiding further delisting risks.
Investor Sentiment
How existing and potential investors react to the split will be crucial; a negative response could exacerbate the underlying issues driving the low share price.
Clinical Progress
The company’s ability to demonstrate meaningful clinical progress with CUE-401 and other pipeline assets will ultimately be the primary driver of long-term value, overshadowing the effects of the reverse split.

Cue Biopharma Presents Data on Treg-Inducing Candidate CUE-401

Event summary

  • Cue Biopharma will present preclinical data on CUE-401 at IMMUNOLOGY2026, April 18, 2026.
  • The data focuses on CUE-401’s ability to induce FOXP3+ iTregs from conventional CD4+ T cells.
  • CUE-401 is a bifunctional TGF-beta/IL-2 fusion protein designed to restore immune homeostasis.
  • Natasha M. Girgis, Director, Translational Pharmacology, will present the data.

The big picture

Cue Biopharma's CUE-401 represents a novel approach to treating autoimmune and inflammatory diseases by directly modulating T cell populations. The company's focus on induced Treg expansion, inspired by Nobel Prize-winning research, aligns with the broader trend towards targeted immunotherapies. However, the complexity of the mechanism and the company’s financial situation introduce significant risks that will influence its trajectory.

What we're watching

Clinical Translation
The preclinical data's translation to human clinical trials will be critical; the complex mechanism of action involving TGF-beta and IL-2 coordination introduces potential challenges in efficacy and safety.
Regulatory Pathway
Given the novel mechanism and potential for broad application across autoimmune and inflammatory diseases, the regulatory pathway for CUE-401 will be closely watched, particularly regarding endpoints and trial design.
Financial Stability
Cue Biopharma’s stated “going concern” determination highlights financial vulnerability; successful data readouts and potential partnerships will be essential to secure ongoing funding and development.

Cue Biopharma Secures $7.5M Milestone in Boehringer Ingelheim Collaboration

Event summary

  • Cue Biopharma will receive a $7.5 million milestone payment from Boehringer Ingelheim.
  • The payment is tied to the selection and approval of the first compound for lead optimization.
  • The collaboration focuses on developing bispecific molecules for autoimmune and inflammatory diseases.
  • Cue Biopharma is eligible for up to $337.5 million in additional milestone payments and royalties.

The big picture

This milestone payment validates Cue Biopharma’s Immuno-STAT platform and its potential to address the significant unmet need in autoimmune and inflammatory disease treatment. The collaboration with Boehringer Ingelheim, a major player in the pharmaceutical industry, provides Cue Biopharma with crucial financial support and expertise. However, the company's financial health remains a key risk factor, and the success of the collaboration hinges on the continued development of CUE-501 and CUE-401.

What we're watching

Clinical Progress
The advancement of CUE-401 towards clinical trials will be a key indicator of Cue Biopharma’s overall pipeline progress and ability to execute on its strategy.
Collaboration Depth
Whether Boehringer Ingelheim expands the collaboration beyond CUE-501 to include additional bispecifics will signal the strength of the partnership and its potential for long-term value creation.
Financial Stability
Given the company's recent 'going concern' determination, the consistent receipt of milestone payments and ability to secure further funding will be critical to sustaining operations.

Cue Biopharma CEO Departs Amid Clinical Advancement Push

Event summary

  • Usman Azam has resigned as President and CEO of Cue Biopharma, effective March 26, 2026.
  • Lucinda Warren, currently CFO and Business Officer, has been appointed interim CEO.
  • Warren previously held business development roles at Johnson & Johnson and Janssen.
  • The board cited Warren's successful deal-making, including collaborations with Boehringer Ingelheim and ImmunoScape.
  • Cue Biopharma aims to advance CUE-401 into the clinic by the second half of 2026.

The big picture

The sudden departure of a CEO, particularly one with a relatively short tenure, raises questions about strategic alignment and operational performance. Cue Biopharma's focus on modulating T cells for autoimmune diseases is a competitive area, and the company's ability to execute on its Immuno-STAT® platform will be key to its success. The appointment of a CFO to the interim CEO role suggests a prioritization of financial stability and deal-making expertise during this transition.

What we're watching

Governance Dynamics
The appointment of an interim CEO, especially one from within, often signals underlying board concerns or strategic disagreements that may impact long-term direction.
Execution Risk
Warren's success in deal-making doesn't guarantee success in leading a clinical-stage company; the ability to translate deal flow into clinical milestones will be critical.
Clinical Progress
The stated timeline for CUE-401 entry into the clinic is aggressive; delays could reflect underlying development challenges or resource constraints.

Cue Biopharma to Detail Treg Modulation Strategy at R&D Day

Event summary

  • Cue Biopharma will host a virtual R&D Day on April 7, 2026, at 10:00 AM EDT.
  • The event will feature KOLs Richard DiPaolo, PhD, and Jonathan Kay, MD, discussing CUE-401.
  • CUE-401 is the company’s lead asset targeting autoimmune and inflammatory diseases.
  • DiPaolo’s research focuses on regulatory T cells (Tregs) and their role in autoimmunity.
  • Kay has extensive experience in clinical trials for therapies targeting rheumatic diseases.

The big picture

Cue Biopharma’s Immuno-STAT platform represents a novel approach to autoimmune disease treatment, aiming to induce tolerance rather than broad immunosuppression. The R&D Day provides a crucial window into the validation of this strategy and the progress of CUE-401, which faces the challenge of demonstrating efficacy and safety in a competitive market with significant unmet need. The involvement of established KOLs suggests a degree of external validation, but the data presented will be the ultimate arbiter of the asset’s potential.

What we're watching

Clinical Data
The success of CUE-401 hinges on demonstrating meaningful clinical efficacy and safety profiles, and the R&D Day will be a key opportunity to assess early data trends.
Regulatory Pathway
Given the complexity of modulating T cell function, the FDA’s acceptance of CUE-401’s mechanism of action and clinical trial design will be a critical determinant of its commercial viability.
Competitive Landscape
The autoimmune and inflammatory disease space is crowded; the R&D Day will reveal how Cue Biopharma differentiates CUE-401 from existing and emerging therapies.

Cue Biopharma Secures Funding, Expands Cell Therapy Focus

Event summary

  • Cue Biopharma raised $10.2 million via a public offering in Q4 2025.
  • The company entered a strategic collaboration and license agreement with ImmunoScape, receiving $9.5 million upfront and a 40% equity stake in ImmunoScape.
  • Cue Biopharma is advancing CUE-401, its lead asset for autoimmune and inflammatory diseases, towards Investigational New Drug (IND) readiness.
  • Research and development expenses increased significantly in 2025, primarily due to CUE-401 development and the ImmunoScape collaboration.

The big picture

Cue Biopharma’s strategic shift towards cell therapy development, coupled with the recent funding round, signals a broader industry trend of leveraging innovative technologies to address unmet needs in oncology. The ImmunoScape collaboration represents a significant bet on a new therapeutic modality, but also introduces dependencies and potential integration challenges. The company's ability to execute on this strategy will be crucial for long-term value creation.

What we're watching

Clinical Progress
The success of CUE-401’s IND application and subsequent clinical trial results will be critical to validating Cue Biopharma’s Immuno-STAT® platform and attracting further investment.
Financial Sustainability
Given the company's current cash position and ongoing R&D expenses, the ability to secure additional funding or demonstrate revenue generation will be key to sustaining operations.
Collaboration Synergy
The integration of ImmunoScape’s cell therapy approach and Cue Biopharma’s Immuno-STAT® platform will need to demonstrate tangible progress to justify the upfront investment and potential royalty payments.

Cue Biopharma Presents TGF-β/IL-2 Fusion Data, Highlights Tolerogenic Mechanism

Event summary

  • Cue Biopharma will present in vitro data for CUE-401 at the World Immune Regulation Meeting (WIRM) 2026 in Davos, Switzerland, March 11-14.
  • The data demonstrate CUE-401's ability to inhibit proinflammatory immune cells via TGF-β and suppress proinflammatory cytokine responses.
  • CUE-401 combines a TGF-beta ‘breathing-mask’ moiety with Cue Biopharma’s IL-2 mutein, inspired by 2025 Nobel Prize-winning science.
  • Natasha M. Girgis, Director, Translational Pharmacology, will present the data on March 12, 2026.

The big picture

Cue Biopharma’s CUE-401 represents a novel approach to treating autoimmune and inflammatory diseases by leveraging the body’s own immune regulatory mechanisms. The company’s focus on TGF-β and IL-2 signaling, building on Nobel Prize-winning research, positions it within a growing trend toward more targeted and tolerogenic therapies. However, the complexity of the mechanism and the competitive landscape present significant hurdles to commercial success.

What we're watching

Clinical Translation
The in vitro data’s relevance to clinical efficacy remains to be seen; the company will need to demonstrate similar effects in vivo and ultimately in human trials to validate the therapeutic potential of CUE-401.
Regulatory Pathway
Given the complexity of the mechanism of action, the FDA may require extensive data on safety and efficacy, potentially lengthening the regulatory review process and increasing development costs.
Competitive Landscape
The autoimmune and inflammatory disease space is crowded; CUE-401’s differentiated mechanism, combining TGF-β and IL-2, will need to demonstrate a clear advantage over existing and emerging therapies to gain market share.

Cue Biopharma Shows Tolerability Data for Autoimmune Candidate CUE-401

Event summary

  • Cue Biopharma released preclinical safety and tolerability data for CUE-401, a lead autoimmune asset.
  • Two non-GLP studies in mice and non-human primates (NHPs) showed CUE-401 was well-tolerated at escalating doses.
  • Repeat dosing at 3 mg/kg showed less tolerability than repeat dosing at 1 mg/kg in NHPs.
  • CUE-401 combines a TGF-beta breathing-mask moiety with Cue Biopharma’s IL-2 mutein, inspired by 2025 Nobel Prize-winning science.

The big picture

Cue Biopharma’s CUE-401 represents a novel approach to autoimmune disease treatment, leveraging TGF-beta and IL-2 modulation to induce immune tolerance. The preclinical data, while positive, are a preliminary step in a long and risky development pathway, as autoimmune therapies often face challenges in efficacy and safety. The company’s reliance on a complex, multi-faceted mechanism of action introduces significant execution risk, requiring precise control and validation throughout clinical trials.

What we're watching

Clinical Trials
The timing and design of the planned Investigational New Drug (IND) filing for CUE-401 will be critical to assess the company's commitment and confidence in the data.
Dose Optimization
The observed difference in tolerability between the 1 mg/kg and 3 mg/kg repeat doses in NHPs suggests that careful dose optimization will be essential for successful clinical development.
Mechanism of Action
How effectively CUE-401’s three-pronged mechanism (TGF-beta, IL-2, FOXP3 conversion) translates to clinical efficacy in autoimmune disease will determine its ultimate value proposition.

Cue Biopharma Elevates CBO to Combined Financial and Business Role

Event summary

  • Lucinda Warren, currently Cue Biopharma’s Chief Business Officer (CBO), has been appointed Chief Financial and Business Officer (CFBO), effective February 9, 2026.
  • Warren has held the CBO role since September 2024.
  • Prior to Cue Biopharma, Warren held VP Business Development roles at Johnson & Johnson (2014-2024).
  • Warren brings over 30 years of experience in the pharmaceutical and biotechnology sectors.
  • The move is reportedly intended to support the advancement of CUE-401, Cue Biopharma’s lead autoimmune asset, toward clinical trials.

The big picture

The appointment of a combined CFBO signals a strategic shift towards integrating financial and business development functions, particularly crucial for clinical-stage biopharma companies navigating capital constraints and regulatory pathways. Warren’s experience at Johnson & Johnson, a company with significant resources, suggests Cue Biopharma is seeking to professionalize its operations and accelerate growth. The move also highlights the increasing demand for executives with both financial and operational expertise in the biotech sector.

What we're watching

Financial Stability
Given the company’s recent acknowledgement of a ‘going concern’ determination, Warren’s expanded role will be scrutinized for its impact on financial planning and resource allocation.
Clinical Progression
The stated focus on advancing CUE-401 towards the clinic suggests a heightened emphasis on clinical trial execution and potential regulatory hurdles.
Business Development
Warren’s extensive business development background suggests potential for increased M&A activity or strategic partnerships to bolster Cue Biopharma’s pipeline.

Cue Biopharma Raises $10 Million in Discounted Offering

Event summary

  • Cue Biopharma priced a public offering of 35,714,286 shares (or pre-funded warrants) and warrants at $0.28 per unit.
  • The offering is expected to generate approximately $10 million in gross proceeds.
  • The underwriters have a 30-day option to purchase an additional 5,357,140 shares and warrants.
  • The offering closes on or about December 22, 2025.
  • The securities are being offered pursuant to an effective shelf registration statement filed with the SEC on May 9, 2023.

The big picture

Cue Biopharma’s reliance on public offerings to fund operations highlights the challenges faced by clinical-stage biopharma companies, particularly those with limited revenue and a history of losses. The discounted pricing of this offering signals investor skepticism regarding the company’s prospects and underscores the need for tangible clinical milestones to regain market confidence. This capital raise is intended to address the company's recent 'going concern' determination, but the underlying financial issues remain a significant risk.

What we're watching

Financial Stability
The company's 'going concern' determination, coupled with this heavily discounted offering, suggests significant financial pressure; the success of future financing rounds will be critical to its survival.
Shareholder Dilution
The substantial number of shares and warrants issued will significantly dilute existing shareholders, potentially impacting the stock's performance and investor confidence.
Clinical Progress
The company's ability to demonstrate meaningful progress in its clinical trials will be essential to justifying the current valuation and attracting future investment.

Cue Biopharma Seeks Capital Amidst Going Concern Warning

Event summary

  • Cue Biopharma is launching a public offering of common stock and warrants, potentially including pre-funded warrants.
  • The offering size is currently undefined, with underwriters holding an option to purchase up to 15% more shares and warrants.
  • The offering is being conducted under an existing S-3 shelf registration statement filed with the SEC in May 2023.
  • Cue Biopharma has disclosed a 'going concern' determination, indicating potential issues with short-term financial viability.
  • H.C. Wainwright & Co. is the sole book-running manager, with Newbridge Securities Corporation acting as co-manager.

The big picture

Cue Biopharma's public offering underscores the ongoing challenges faced by clinical-stage biotech companies seeking capital in a risk-off market. The 'going concern' designation highlights the precarious financial position of many smaller biopharma firms, particularly those reliant on external funding to advance their pipelines. This offering is a crucial test of investor confidence in Cue Biopharma's Immuno-STAT platform and its potential to disrupt autoimmune disease treatment.

What we're watching

Capital Raise
The ultimate size and pricing of the offering will reveal the market’s appetite for Cue Biopharma’s stock given its financial challenges and early-stage pipeline.
Financial Stability
Whether the capital raised will be sufficient to resolve the ‘going concern’ determination and sustain operations beyond the next twelve months is critical to long-term viability.
Clinical Progress
The success of Cue Biopharma's clinical trials will be paramount in justifying the current valuation and attracting further investment, given the inherent risks associated with early-stage drug development.
CID: 555